Soft Tissue Sarcoma Panel (SNVs, InDels and Fusions)

The Soft Tissue Sarcoma Panel is an advanced diagnostic tool utilizing high-throughput next-generation sequencing on sarcoma tissue samples. This innovative assay identifies crucial genomic alterations, including SNVs, InDels, and Fusions, delivering vital diagnostic, prognostic, and therapeutic insights for patients. With coverage of 110 key sarcoma-related genes aligned with the latest NCCN guidelines, it comprehensively assesses biomarkers in sarcoma malignancies. Operating at a minimum depth of 250X on a validated Illumina sequencing platform, it ensures accuracy. Genomic alterations and fusions are meticulously prioritized, classified, and reported according to AMP-ASCO-CAP and NCCN guidelines, empowering precision medicine in sarcoma care.

Disclaimer: In no event shall the liability of TATA 1MG exceed the amount of actual cost of test charges incurred by the customer as stated on the invoice issued by Tata 1mg.